Rauwolscine

Cat. No.:	HY-12710
CAS No.:	131-03-3
Molecular Formula:	$C_{21}H_{26}N_2O_3$
Molecular Weight:	354.44
Target:	Adrenergic Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	-20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



BIOLOGICAL ACTIVITY

Description	Rauwolscine is a selective α2-adrenoceptor antagonist that inhibits tumor growth and induces apoptosis[1].
In Vivo	Rauwolscine (0.5 mg/kg, daily) reduces tumor growth by enhancing apoptosis and reducing cell proliferation in Balb/c female virgin mice[1]. Rauwolscine (i.v., 2.24 mg/kg) can significantly release lick-shock conflict responding in rats similar to the α agonist clonidine (0.022 mg/kg) and the benzodiazepine diazepam (0.5 mg/kg) [2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. A Bruzzone, et al. Alpha2-adrenoceptor action on cell proliferation and mammary tumour growth in mice. Br J Pharmacol. 2008 Oct;155(4):494-504.

[2]. S La Marca, et al. The alpha-2 antagonists idazoxan and rauwolscine but not yohimbine or piperoxan are anxiolytic in the Vogel lick-shock conflict paradigm following intravenous administration. Life Sci. 1994;54(10):PL179-84.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA